Keller Rohrback Announces Tenth Circuit Victory
in EpiPens Case Against Mylan and Pfizer
Today, the Tenth Circuit Court of Appeals rejected Defendants’ bid to appeal the district court’s class certification order for a nationwide RICO class in In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, the multidistrict litigation against Mylan and Pfizer that seeks to hold Defendants accountable for forcing consumers to pay inflated prices for EpiPens.
Today’s order allows the class action to move forward toward trial, which is scheduled for April 2021.
“We are thrilled that the Tenth Circuit agrees with Plaintiffs that ‘interrupting the district court proceedings with an interlocutory appeal at this time’ is not ‘necessary or warranted.’ We look forward to filing our joint Proposed Pretrial Order on Friday and continuing with trial preparations,” said Managing Partner Lynn Sarko, who serves as Plaintiffs’ co-lead counsel in the case.
To learn more about the case and how to potentially pursue a claim, please go here.
About Keller Rohrback L.L.P.
Keller Rohrback is a nationally recognized law firm aimed at obtaining justice for our communities. With offices in Seattle, Phoenix, New York, Santa Barbara, Oakland, and Missoula, Keller Rohrback serves as lead and co-lead counsel in high-impact litigation throughout the country. Our Complex Litigation Group is proud to offer its experience to clients nationwide, and our trial lawyers have obtained judgments and settlements in excess of $23.25 billion.
Attorney Advertising. Prior results do not guarantee a similar outcome. Not licensed to practice law in all states. Please refer to krcomplexlit.com for details.